Feminax Ultra:グローバル医薬品動向2014(販売量、特許、APIメーカー、治験動向など)

◆英語タイトル:Feminax Ultra-Drug Insights,2014
◆商品コード:DIDR2014243
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2014年版(※最新版はお問い合わせください)
◆ページ数:25以上
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD1,000 ⇒換算¥108,000見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,000 ⇒換算¥216,000見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD3,000 ⇒換算¥324,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

DelveInsight’s pharmaceuticals report, “Feminax Ultra – Drug Insights, 2014” provides Feminax Ultra marketed details and API Manufacturers details across the globe along with the location. In addition, it covers sales estimates for the US, detailed clinical assessment of the drug, patent details, route of synthesis, competitive landscape, and analysis of sales performance during the forecast period (2011-2015). The report also includes SWOT analysis for the drug. This report is built using data and information sourced from DelveInsight proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by DelveInsight team of industry experts.

Data Sources
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated drug.


• A review of the Feminax Ultra based on information derived from company and industry-specific sources
• Coverage of the Marketed data of the Feminax Ultra on the basis of MOA, target, dosage, route of administration, molecule type, strength, Chemical type and ATC Classification
• Coverage of the United States Drug Master File (US DMF), Active Substance Master File/EU DMF and API Manufactures in China & India for Schizophrenia drugs with location details
• Patent Expiry Timeline and Exclusivity Details
• Route of Synthesis of the API
• Global Forecasted Sales Figure from 2011-2015
• Qualitative and quantitative assessment of market space
• SWOT Analysis

• Evaluate the marketing status and exclusivity details of Feminax Ultra to exploit opportunities for generic drug development opportunities.
• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Feminax Ultra.
• API intelligence over Feminax Ultra and gaining primary intelligence over Active Ingredients manufacturers across the globe.
• Understanding the chemical route of synthesis of Feminax Ultra.
• Uncovering opportunities in the rapidly growing the US market
• Stay ahead of competition by understanding the changing competitive landscape
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
• Obtain sales forecast for currently marketed drug for 2011-2015

【レポートの目次】

• Drug Overview
• Global Sales Assessment
• Product Description
• Mechanism of Action
• Pharmacodynamic Properties
• Pharmacokinetic Properties
• Marketed Details for the United States
• Marketed Details for the Europe
• Patent Information
• Patent and Exclusivity Expiry Assessment United States (US)
• Patent Numbers and Expiry Details
• Patent Details
• Route of Synthesis
• Global API Manufacturers Assessment
• The United States Drug Master File (US DMF)
• The Europe Drug Master File (EUDMF)/Active Substance Master File (ASMF)
• The Active Pharmaceutical Ingredient (API) Manufacturers in the ASIA Region
• The Active Pharmaceutical Ingredient (API) Manufacturers by the United States Drug Master (DMF) File Status
• The Active Pharmaceutical Ingredient (API) Manufacturers by Region
• The Active Pharmaceutical Ingredient (API) Manufacturers by Location/Countries
• Generic Players
• The Pipeline Coverage
• Clinical Trials Information
• Clinical Trials by Zone
• Company Profile
• Summary
• Company Financials
• SWOT Analysis
• References
• Appendix
• Methodology
• About DelveInsight
• Contact Us
• Disclaimer

• Feminax Ultra, Market, Global Sales (in USD), 2014
• Feminax Ultra, Description
• Feminax Ultra, Marketed Details the United States (US)
• Feminax Ultra, Marketed Details the Europe (EU)
• Feminax Ultra, Patent/Exclusivity Expiry (Year), 2014
• Feminax Ultra, Patent Number Specific Patent Expiry (Year), 2014
• Feminax Ultra, Patent Details
• Feminax Ultra, Route of Synthesis
• Feminax Ultra, the United States Drug Master File (US DMF), 2014
• Feminax Ultra, the Europe Drug Master File (EUDMF)/Active Substance Master File (ASMF), 2014
• Feminax Ultra, the API Manufacturers, China, 2014
• Feminax Ultra, the API Manufacturers, India, 2014
• Feminax Ultra, the API Manufacturers by the US DMF Status, 2014
• Feminax Ultra, the API Manufacturers by Region, 2014
• Feminax Ultra, the API Manufacturers by Location/Countries, 2014
• Feminax Ultra, Generic Players, 2014
• Feminax Ultra, Pipeline Drug Details, 2014
• Feminax Ultra, Clinical Trials, 2014
• Feminax Ultra, Clinical Trials by Zone, 2014
• Company Overview, 2014
• Feminax Ultra, SWOT Analysis, 2014
• Phase III Pipeline Therapeutics, 2014

• Feminax Ultra, Market, Global Sales (in million USD), 2014
• Feminax Ultra, Global Sales % Change, 2014
• Feminax Ultra, Patent/Exclusivity Expiry (Year), 2014
• Feminax Ultra, Patent Number Specific Patent Expiry (Year), 2014
• Feminax Ultra, Route of synthesis
• Feminax Ultra, the API Manufacturers by the US DMF Status (%), 2014
• Feminax Ultra, the API Manufacturers by Region, 2014
• Feminax Ultra, the API Manufacturers by Location/Countries, 2014
• Feminax Ultra, Generic Players, 2014
• Feminax Ultra, Clinical Trials by Zone (%), 2014

【レポートのキーワード】

Women's Health、Feminax Ultra、医薬品、販売量、特許、医薬品有効成分(API)メーカー、治験動向 、製薬、企業

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[Feminax Ultra:グローバル医薬品動向2014(販売量、特許、APIメーカー、治験動向など)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆